Lung Cancer Clinical Trials in Portland

Showing 121-140 of 324 trials

A Study to Investigate LYL845 in Adults With Solid Tumors

NCT05573035

This is an open-label, multi-center, dose-escalation study with expansion cohorts, designed to evaluate the safety and anti-tumor activity of LYL845, an epigenetically reprogrammed tumor infiltrating lymphocyte (TIL) therapy, in participants with relapsed or refractory (R/R) metastatic or locally advanced melanoma, non-small cell lung cancer (NSCLC), and colorectal cancer (CRC).

MelanomaNon-small Cell Lung CancerColorectal Cancer

Lyell Immunopharma, Inc.39 participantsStarted Dec 2022

Sacramento, California, United States • Santa Monica, California, United States • Stanford, California, United States +15 more locations

No Longer Available< 1 mile

Medical Access Program for Patritumab Deruxtecan

NCT06099639

The purpose of this Medical Access Program is to provide access to HER3-DXd for eligible patients with NSCLC who, in their treating physician's opinion, have an unmet clinical need which cannot be treated with approved and commercially available drugs and who cannot enter a clinical trial prior to commercial availability.

Epidermal Growth Factor Receptor (EGFR)-Mutated Non Small Cell Lung Cancer

Daiichi Sankyo

Springdale, Arkansas, United States • Los Angeles, California, United States • Aurora, Colorado, United States +18 more locations

A Study to Investigate LYL845 in Adults With Solid Tumors

Medical Access Program for Patritumab Deruxtecan

Lung Cancer Trials in Other Cities

Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

Improving Decision-Making Encounters in Lung Cancer Using a Low-Literacy Conversation Tool

Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors

A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer

A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors

MGD019 DART® Protein in Unresectable/Metastatic Cancer

Avelumab in First-line NSCLC (JAVELIN Lung 100)

HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy

Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)

Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation

Testing the Effects of MK-3475 (Pembrolizumab) With or Without the Usual Chemotherapy Treatment for Patients 70 Years of Age and Older With Advanced Non-small Cell Lung Cancer

A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer

Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC

Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer

(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations

LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib

Oral AMXT 1501 Dicaprate in Combination With IV DFMO

A Trial of Pembrolizumab in Combination With Chemotherapy and Radiotherapy in Stage III NSCLC (KEYNOTE-799, MK-3475-799)

Other Conditions in Portland